Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Cystic Fibrosis (Jan 2020)

Posted by Matt Breese on Jan 10, 2020

Find me on:

According to our recent payer coverage analysis for cystic fibrosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for cystic fibrosis treatments shows that under the pharmacy benefit, almost 45% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Cystic Fibrosis_1Q2020Data snapshot as of Q1 2020

Trends: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators (Vertex Pharmaceuticals’ Trikafta, Symdeko, Orkambi and Kalydeco) are the first type of CF therapy to treat the root cause of the disease rather than the symptoms. Although costly, these therapies have made a large impact on market value.  

To read the full Reality Check on Cystic Fibrosis treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing